Drug Trial Radar · NCT03630315
CLN-0046: Treatment of AMD Subjects With OTX-TKI
Last checked: Nov 20, 2026Latest source record: Jul 10, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
29
Actual
Start
Feb 18, 2019
Primary completion
Jan 10, 2024
Study completion Jan 10, 2024
Sponsor
- Lead sponsor
- Ocular Therapeutix, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the safety, tolerability and efficacy of OTX-TKI for intravitreal use, in subjects who have neovascular age-related macular degeneration (AMD).
Conditions
- Neovascular Age-related Macular Degeneration
Interventions
OTX-TKIDrug
OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
OTX-TKIDrug
OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
OTX-TKIDrug
OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
OTX-TKIDrug
OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
Anti-VEGFDrug
Standard of care therapy used to block vascular endothelial growth factor
OTX-TKIDrug
OTX-TKI is a dried polyethylene glycol-based hydrogel fiber containing dispersed microcrystals of a small molecule tyrosine kinase inhibitor (TKI).
Anti-VEGFDrug
Standard of care therapy used to block vascular endothelial growth factor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment emergent adverse events for each subjectTime frame: 9 months
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Ocular Therapeutix, Inc.
Adelaide, Australia
Ocular Therapeutix, Inc.
Albury, Australia
Ocular Therapeutix, Inc.
Melbourne, Australia
Ocular Therapeutix, Inc.
Sydney, Site 1, Australia
Ocular Therapeutiux, Inc.
Sydney, Site 2, Australia
Ocular Therapeutiux, Inc.
Sydney, Site 3, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.